<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 27, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6263931/global-kif18a-targeting-therapies-clinical?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=g6j46s&amp;utm_campaign=2339151+-+Global+KIF18A+Targeting+Therapies+Market+Insights+Report+2026%3a+Profiles+Volastra%2c+Accent%2c+Insilico%2c+Amgen%2c+Aurigene%2c+Tailor+Bio+and+Other+Key+Players&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global KIF18A Targeting Therapies Clinical Innovation, Combination Treatment Strategies, Therapeutic Approaches, Technology Platforms &amp; Clinical Trials Insight 2026">"Global KIF18A Targeting Therapies Clinical Innovation, Combination Treatment Strategies, Therapeutic Approaches, Technology Platforms &amp; Clinical Trials Insight 2026"</a> has been added to ResearchAndMarkets.com's offering. The latest Global KIF18A-Targeting Therapies Clinical Innovation and Clinical Trials Insight 2026 Report provides a comprehensive assessment of the emerging KIF18A inhibitor landscape, including clinical development programs, combination treatment strategies, therapeutic approaches, technology platforms, competitive intelligence and commercialization opportunities. Report Highlights <ul><li>First commercial availability of a KIF18A-targeting therapy expected by 2032</li><li>Highest clinical development stage currently identified as Phase I/II</li><li>More than 20 KIF18A-targeting therapies covered across the development landscape</li><li>Clinical trial analysis by company, country, indication and development phase</li><li>Assessment of therapeutic approaches targeting KIF18A</li><li>Company-level analysis of drug discovery and development technology platforms</li><li>Detailed review of the global competitive landscape</li></ul> Growing Need for KIF18A-Targeting Cancer Therapies KIF18A-targeting therapies are becoming an important area of precision oncology as research continues to establish chromosomal instability as a druggable vulnerability. KIF18A is a mitotic motor protein involved in chromosome alignment and spindle organization during cell division. Chromosomally unstable tumor cells can demonstrate a heightened dependency on KIF18A, supporting its development as a synthetic lethal target across multiple solid tumors. This therapeutic strategy is being investigated in high-grade serous ovarian cancer, triple-negative breast cancer, colorectal cancer, lung cancer and other malignancies associated with chromosomal instability. KIF18A inhibition can disrupt mitosis, promote chromosome misalignment and prolonged cell-cycle arrest, and ultimately induce cancer cell death. These characteristics have accelerated the development of selective small-molecule KIF18A inhibitors for patients with advanced, resistant or difficult-to-treat cancers. The report evaluates KIF18A tumor biology, drug discovery strategies, clinical pipeline trends, biomarker-driven patient selection and commercial prospects. It is designed to support pharmaceutical companies, biotechnology firms, investors, researchers and other oncology stakeholders seeking to understand the competitive dynamics and future opportunities within the global KIF18A-targeting therapies market. KIF18A Inhibitor Clinical Trials and Pipeline Analysis Clinical development will be central to determining the future role of KIF18A inhibitors in precision cancer treatment. Multiple investigational programs are progressing through early-stage clinical evaluation across solid tumors characterized by chromosomal instability. Pipeline candidates covered in the report include oral small-molecule KIF18A inhibitors such as sovilnesib, orvanesib (VLS-1488), ATX-295 and MEN2501. The report analyzes KIF18A clinical trials by sponsoring company, cancer indication, geography, development phase, patient population and regulatory milestone. It also examines the expansion of KIF18A inhibitors beyond monotherapy. Combination treatment strategies involving microtubule inhibitors, chemotherapy and other targeted medicines are attracting increasing attention because of their potential to improve treatment activity, address resistance mechanisms and expand the eligible patient population. Companies Developing KIF18A-Targeting Therapies The competitive landscape includes biotechnology and pharmaceutical companies developing therapies that exploit chromosomal instability. Volastra Therapeutics is a prominent participant, with KIF18A inhibitor programs including sovilnesib and VLS-1488. Its development strategy incorporates biomarker-based methods intended to identify patients whose tumors are dependent on KIF18A. Accent Therapeutics is advancing ATX-295, an oral KIF18A inhibitor under clinical evaluation for advanced chromosomally unstable solid tumors. Insilico Medicine has also strengthened the pipeline through MEN2501, which has progressed into clinical development. Additional companies contributing to KIF18A-related oncology research include Amgen, Aurigene Oncology and Tailor Bio. Technology Platforms, Collaborations and Licensing Agreements Technology platforms focused on chromosomal instability are supporting target identification, compound discovery and biomarker-led clinical development. Volastra Therapeutics' CINtech platform applies insights from chromosomal instability biology to identify synthetic lethal oncology targets, including dependencies involving chromosome alignment machinery and KIF18A. This approach supports the development of selective therapies for tumors with high levels of chromosomal instability while enabling more precise patient-selection strategies. Strategic collaborations and licensing agreements are also expected to influence market growth. Insilico Medicine licensed MEN2501 to Stemline Therapeutics, a Menarini Group company, through an agreement valued at more than US$550 million. The advancement of this program into Phase I clinical trials reflects increasing pharmaceutical and commercial interest in KIF18A as an oncology target. Future Outlook for the KIF18A-Targeting Therapies Market Future development is expected to emphasize broader clinical applications, improved biomarker-guided patient selection and optimized combination therapy strategies. Advances in chromosomal instability profiling, whole-genome doubling assessment and Rb-pathway-associated biomarkers may help identify patients most likely to benefit from KIF18A inhibition. With several KIF18A-targeting agents progressing through clinical trials, the commercial outlook for this therapeutic class continues to strengthen. Ongoing innovation in small-molecule design, clinical trial execution, precision oncology biomarkers and strategic partnerships could establish KIF18A inhibition as a significant treatment modality for chromosomally unstable cancers. The report delivers actionable insight into the companies, clinical programs, technologies and market factors shaping this rapidly evolving area of cancer drug development. Key Topics Covered 1. Research Methodology 2. Introduction To KIF18A Targeting Therapies 2.1 Overview Of Kinesin Family &amp; KIF18A 2.2 History &amp; Development 3. Scientific &amp; Biological Background 3.1 Overview Of KIF18A 3.2 Oncogenic Role &amp; Therapeutic Rationale 4. Therapeutic Approaches Targeting KIF18A 4.1 Small Molecule Inhibitors 4.2 RNAi Based Strategies 5. KIF18A Targeting Therapies R&amp;D Trends by Indication 5.1 Solid Tumors 5.2 Hematological Malignancies 6. KIF18A Targeting Therapies Combination Strategies by Drug Class 7. KIF18A Targeting Therapies Market Potential Overview 7.1 Current Scenario 7.2 Future R&amp;D &amp; Commercial Opportunities 8. KIF18A Targeting Therapies Development Technology Platforms 9. KIF18A Targeting Therapies Clinical Trials Overview 9.1 by Phase 9.2 by Country 9.3 by Company 9.4 by Indication 9.5 by Priority Status 10. KIF18A Targeting Therapies Clinical Trials Insight by Company, Indication &amp; Phase 10.1 Research 10.2 Preclinical 10.3 Phase I 10.4 Phase I/II 11. KIF18A Targeting Therapies Market Dynamics 11.1 Drivers &amp; Opportunities 11.2 Challenges &amp; Restraints 12. Competitive Landscape 12.1 Accent Therapeutics 12.2 Amgen 12.3 Apeiron Therapeutics 12.4 Aurigene Oncology 12.5 Genhouse Bio 12.6 GeneScience Pharmaceuticals 12.7 Iambic Therapeutics 12.8 Innogate Pharma 12.9 Insilico Medicine 12.10 Satya Pharma 12.11 Tailor Bio 12.12 Volastra List of Figures Figure 2-1: Kinesin Family Overview Figure 2-2: KIF18A - Overview Figure 2-3: KIF18A Research - Discovery &amp; Evolution Figure 3-1: KIF18A - Role In Mitosis Figure 3-2: KIF18A - Expression In Normal &amp; Cancer Tissues Figure 3-3: KIF18A As Therapeutic Target In Cancer Figure 3-4: KIF18A - Synthetic Lethality Pathway Figure 3-5: KIF18A As Prognostic Marker In Cancer Figure 4-1: Small Molecule KIF18A Inhibitors - Mechanism Of Action Figure 4-2: RNAi-Mediated Silencing Of KIF18A - Mechanism Of Action Figure 4-3: KIF18A RNAi - Effects On Tumor Cell Phenotypes Figure 5-1: SOVI-2302 Phase 1 (NCT06084416) Study - Initiation &amp; Completion Year Figure 5-2: VLS-1488-2201 Phase 1/2 (NCT05902988) Study - Initiation &amp; Completion Year Figure 5-3: ATX-295-001 Phase 1/2 (NCT06799065) Study - Initiation &amp; Completion Year Figure 5-4: GH2616-101 Phase 1 (NCT06329206) Study - Initiation &amp; Completion Year Figure 5-5: KIF18A In Hematological Malignancies - Role &amp; Therapeutic Opportunity Figure 7-1: KIF18A Targeting Therapies - Future Opportunities Figure 8-1: Chemistry42 - Insilico Medicine Figure 8-2: CINtech Platform - Volastra Therapeutics Figure 8-3: Unnamed Platform - Accent Therapeutics Figure 8-4: Chromosomal Instability Platform - Tailor Bio Figure 9-1: Global - Number Of KF18A Targeting Therapies In Clinical Trials by Phase, 2026 Figure 9-2: Global - Number Of KF18A Targeting Therapies In Clinical Trials by Country, 2026 Figure 9-3: Global - Number Of KF18A Targeting Therapies In Clinical Trials by Company, 2026 Figure 9-4: Global - Number Of KF18A Targeting Therapies In Clinical Trials by Indication, 2026 Figure 9-5: Global - Number Of KF18A Targeting Therapies In Clinical Trials by Priority Status, 2026 Figure 11-1: KIF18A Targeting Therapies Market - Drivers &amp; Opportunities Figure 11-2: KIF18A Targeting Therapies Market - Challenges &amp; Restraints List of Tables Table 6-1: KIF18A Targeting Therapy In Combination With Chemotherapy Table 6-2: KIF18A Targeting Therapy In Combination With Immunotherapy Table 6-3: KIF18A Targeting Therapy In Combination With Targeted Therapy For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6263931/global-kif18a-targeting-therapies-clinical?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=g6j46s&amp;utm_campaign=2339151+-+Global+KIF18A+Targeting+Therapies+Market+Insights+Report+2026%3a+Profiles+Volastra%2c+Accent%2c+Insilico%2c+Amgen%2c+Aurigene%2c+Tailor+Bio+and+Other+Key+Players&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/3gikrd</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MjM2ZDcwYTgtNTEwMS00YWEzLWI1MjQtMGFjN2RhYzhlNDQ2LTEwMjY3MzctMjAyNi0wOC0yNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global KIF18A Targeting Therapies Market Insights Report 2026: Profiles Volastra, Accent, Insilico, Amgen, Aurigene, Tailor Bio and Other Key Players

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn